Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
Treament |
Trials |
|
|
clinical deterioration | clinical improvement | deaths | viral clearance |
Immunostimulants drugs | 75 | 0.86 [0.74; 1.01], 12 RCTs, I2=0% demonstrated inconclusive result | 1.12 [1.00; 1.25], 19 RCTs, I2=38% demonstrated inconclusive result | 0.90 [0.82; 0.98], 62 RCTs, I2=18% demonstrated low degree of certainty | 3.51 [1.38; 8.94], 7 RCTs, I2=87% low degree of certainty | |
Immunosuppressants drugs | 69 | 0.70 [0.51; 0.96], 11 RCTs, I2=59% demonstrated moderate degree of certainty | 1.25 [1.13; 1.38], 14 RCTs, I2=15% demonstrated low degree of certainty | 0.77 [0.69; 0.86], 44 RCTs, I2=22% demonstrated safety concern inconclusive result | - | |
anti-inflammatory therapies | 26 | 0.18 [0.05; 0.57], 4 RCTs, I2=14% moderate degree of certainty | 10.27 [1.17; 90.18], 1 RCT, I2=0% moderate degree of certainty | 0.99 [0.94; 1.05], 12 RCTs, I2=0% inconclusive result | 1.71 [0.80; 3.64], 1 RCT, I2=0% inconclusive result | |
corticosteroids | 22 | 0.67 [0.44; 1.03], 2 RCTs, I2=0% inconclusive result | 1.44 [0.89; 2.33], 4 RCTs, I2=65% inconclusive result | 0.85 [0.73; 0.99], 15 RCTs, I2=64% demonstrated low degree of certainty | 1.78 [1.06; 3.00], 1 RCT, I2=0% moderate degree of certainty | |
Kinase inhibitors | 3 | - | - | - | - | |
leflunomide | 1 | 1.00 [0.02; 52.54], 1 RCT, I2=0% inconclusive result | - | 1.00 [0.02; 52.54], 1 RCT, I2=0% inconclusive result | - | |
Apilimod | 0 | - | - | - | - | |
inhaled corticosteroids | 0 | - | - | - | - | |
meplazumab | 0 | - | - | - | - | |
pirfenidone | 0 | - | - | - | - | |
Polyinosinic-Polycytidylic Acid | 0 | - | - | - | - | |
sargramostim | 0 | - | - | - | - | |
statins | 0 | - | - | - | - | |
thymosin | 0 | - | - | - | - | |